960 resultados para Medical ethics.
Resumo:
A presente dissertação analisa a possibilidade da prática da eutanásia ativa e voluntária em pacientes com doenças incuráveis à luz da bioética e do direito. O trabalho é de natureza teórica e foi realizado através de pesquisa bibliográfica, que levantou publicações, nacionais e internacionais, inclusive na imprensa, sobre os temas tratados na dissertação, a saber: eutanásia, morte, vida, dignidade, autonomia, princípios bioéticos, liberdade. O levantamento bibliográfico compreendeu, preferencialmente, obras sobre filosofia, ética, bioética, medicina e direito, que permitiram a análise das questões teóricas envolvidas diretamente no estudo. Aborda-se o conceito de morte e suas transformações ao longo dos anos e as distinções necessárias entre os conceitos do fim da vida, que apesar de muito próximos tem suas especificidades. Apresenta-se os princípios bioéticos da não maleficência e da beneficência, com a finalidade de discutir os limites da intervenção médica sobre o paciente, bem como o princípio da autonomia na visão da bioética e do direito, com o intuito de demonstrar que o doente incurável é um ser autônomo, com vontades e desejos que devem ser respeitados. Examinam-se os direitos à vida e a liberdade para fins de ponderação em face do princípio da dignidade da pessoa humana. Diferenciam-se os princípios da sacralidade da vida e da qualidade da vida, na busca de uma integração entre eles e faz-se uma análise do Código de Ética Médica e da Resolução CFM n 1.805 de 2006, que autoriza a ortotanásia, para confrontar os limites da prática médica e da autonomia do paciente. Pontua-se o estado atual da criminalização da eutanásia no ordenamento jurídico brasileiro apontando-se o quão perversa pode se tornar essa criminalização para aquele que sofre e, que através da compaixão laica e da solidariedade deve-se buscar meios hábeis para se permitir a eutanásia, sem deixar de proteger os vulnerados de eventuais abusos. Utilizam-se os casos de Ramón Sampedro e Vincent Humbert, pessoas que por causa de um acidente ficaram tetraplégicas e solicitaram na justiça uma morte digna, para exemplificar os diversos conceitos utilizados nesse trabalho. Por fim, apresentam-se os requisitos pessoais e formais mínimos para que a declaração de vontade de um paciente incurável, que pede uma morte digna, seja respeitada, quando essa vontade é expressa de forma inequívoca por ele, tendo como exemplo, a legislação da Bélgica e da Holanda, onde a eutanásia é permitida observando-se determinados requisitos.
Resumo:
In common with most countries, the childhood immunisation programme in Ireland was founded on a successful public health response to diphtheria. The success of the antidiphtheria public health intervention in Ireland has meant that no case of the disease has been recorded in the state for almost fifty years. This is a significant achievement considering that diphtheria continues to appear annually in many European states, albeit in much reduced numbers on former years. For parents and children of nineteenth, and early twentieth-century Ireland, diphtheria represented the ‘most dreaded disease of childhood’, however, for their modern day counterparts diphtheria is no more than an obscure disease mentioned in leaflets promoting the benefits of childhood immunisation. In Ireland, diphtheria has been consigned to history, and so too have the horrors and mass fatalities once associated with it. But how was this achieved? Was active immunisation received with open arms by public health authorities, the wider medical community, and the general public? This study tackles these questions by undertaking the first historical examination of the issues which underpin the origins of active immunisation in Ireland. It explores the driving forces that shaped the national childhood immunisation programme, and those that opposed them. In addition, it examines the complex social implications attendant on the introduction of this mass public health intervention in an Irish context.
Resumo:
There is widespread agreement that it would be both morally and legally wrong to treat a competent patient, or to carry out research with a competent participant, without the voluntary consent of that patient or research participant. Furthermore, in medical ethics it is generally taken that that consent must be informed. The most widely given reason for this has been that informed consent is needed to respect the patient’s or research participant’s autonomy. In this article I set out to challenge this claim by considering in detail each of the three most prominent ways in which ‘autonomy’ has been conceptualized in the medical ethics literature. I will argue that whilst these accounts support the claim that consent is needed if the treatment of competent patients, or research on competent individuals, is to respect their autonomy, they do not support the claim that informed consent is needed for this purpose.
Resumo:
Food labelling has been overlooked in the emerging body of literature concerning the normative dimensions of food and drink policies. In this paper, I argue that arguments normally advanced in bioethics and medical ethics regarding the “right to know” and the “right not to know” can provide useful normative guidelines for critically assessing existing and proposed food labelling regimes. More specifically, I claim that food labelling ought to respect the legitimate interests and the autonomy of both consumers who seek knowledge about their food in order to make informed dietary choices and consumers who prefer to remain ignorant about the contents and effects of their food in order to avoid the emotional and psychological harm, or more simply the loss of enjoyment, which may result from receiving that information.
Resumo:
Accounts of consent in medical ethics typically assume that consent plays the same role irrespective of the type of treatment. In this paper I argue that this assumption is false. Because of this, obligations to provide information to patients that stem from the need for consent to be valid will not apply to all types of treatment. This does not mean that there are no reasons to provide such information. The second part of the paper maps out what these reasons are and argues that they are grounded in the obligation of beneficence and a duty to warn, not in considerations of respect for autonomy.
Resumo:
The replacement of the European Union (EU) Clinical Trials Directive by the new Clinical Trials Regulation (CTR), which entered into force on 16 June 2014 but will not apply before 28 May 2016, provides an opportunity to review the legal and political context within which this important aspect of research law and policy sits and to reflect on the implications for public health. My aim in this article is to relate the context to the key purposes and aims of EU law and policy on clinical trials in order to explain and clarify its orientation. On that basis, I argue that the CTR and the changes it introduces to the law on clinical trials are part of the EU's continued focus on market optimisation. It is this focus that orients and directs the wider pharmaceutical development pipeline, but that undermines the achievement of key public health objectives.
Resumo:
Around the world the population is ageing in ways that pose new challenges for health care providers. To date these have mostly been formulated in terms of challenges created by increasing costs, and the focus has been squarely on life prolonging treatments. However, this focus ignores the ways in which many older people require life enhancing treatments to counteract the effects of physical and mental decline. This paper argues that in doing so it misses important aspects of what justice requires when it comes to older people.
Resumo:
Non-governmental organizations and transnational networks have been increasingly successful a t gaining influence within issue areas traditionally controlled by the state. In many instances, non-state actors have been instrumental in forcing issues onto the global agenda, have aided in the development or transformation of global regimes, and have participated in securing state compliance for the adoption of new international norms. This paper argues that, consistent with social constructivist theory, ideas are important in influencing state preferences and change may be possible when certain factors are present. I f non-state actors can influence states, it is meaningful to understand how this happens. This paper focuses on a campaign led by Medecins Sans Frontieres that began in the late 1990s to acquire affordable medicines for patients in developing states that could not afford patented drugs. The campaign reached a measure of success in that member states of the World Trade Organization re-negotiated contested terms and meanings within the trade agreement for intellectual property rights and allowed concessions that would benefit lower income states. What factors contributed to the success of the campaign? And what were the most important factors - the issue, the actors or the mechanisms used?
Resumo:
Affiliation: Bryn Williams-Jones : Département de médicine sociale et préventive, Faculté de medecine, Université de Montréal
Resumo:
Le contexte particulier du dopage suscite de nombreuses questions à l'égard des obligations et de la responsabilité des médecins. Suivant le Code médical du Mouvement olympique (2005), les médecins doivent respecter les principes de l'éthique médicale et ceux de l'éthique sportive, comme le fairplay. Il arrive parfois que l'éthique sportive entre en conflit avec l'éthique médicale. Les médecins sont alors confrontés à d'importants dilemmes qui peuvent engager leur responsabilité professionnelle et civile. Ces dilemmes se situent notamment au niveau de l'obligation de soins et du secret professionnel. Par exemple, les médecins peuvent-ils prescrire des médicaments pour contrer les effets néfastes du dopage afin de préserver la santé des athlètes ? La question de la recherche sur l'amélioration de la performance est également préoccupante. En raison du caractère clandestin de cette recherche, il y a lieu de se demander si les médecins qui y participent respectent leurs obligations professionnelles. L'analyse des principaux instruments normatifs applicables en l'espèce démontre que les médecins ne doivent pas être placés dans une situation telle qu'ils doivent refuser de suivre des athlètes de crainte d'être accusés de dopage. De plus, le secret professionnel devrait être maintenu lorsqu'un médecin suit un athlète dopé afin de préserver la relation de confiance. Finalement, l'analyse du contexte de la recherche portant sur l'amélioration de la performance révèle que les médecins ne respectent pas toujours leurs obligations. Les médecins fautifs risquent donc d'engager leur responsabilité professionnelle et civile et de faire face à des sanctions sévères.
Resumo:
Full Text / Article complet
Resumo:
Full Text / Article
Resumo:
This study deals the professional Services civil Liability for deficiency with special reference to medical professionals.the study deals with the characteristics of profession,basis of liability , historical evolution of legal controls on professional services, liability of doctors for negligence under tort law. Expectations to liability for medical negligence are critically evaluated. consent of medical treatment etc are studied